Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
6.28
+0.42 (7.17%)
Dec 20, 2024, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
| Operating Revenue | 67.64 | 67.64 | 79.2 | 86.16 | 97.07 | 122.47 | Upgrade
|
| Revenue | 67.64 | 67.64 | 79.2 | 86.16 | 97.07 | 122.47 | Upgrade
|
| Revenue Growth (YoY) | -14.61% | -14.61% | -8.07% | -11.24% | -20.74% | -40.31% | Upgrade
|
| Gross Profit | 67.64 | 67.64 | 79.2 | 86.16 | 97.07 | 122.47 | Upgrade
|
| Selling, General & Admin | 57.85 | 57.85 | 52.89 | 45.48 | 32.54 | 27.36 | Upgrade
|
| Research & Development | 131.48 | 131.48 | 163.52 | 164.52 | 174.11 | 136.76 | Upgrade
|
| Operating Expenses | 189.33 | 189.33 | 216.41 | 210 | 206.65 | 164.11 | Upgrade
|
| Operating Income | -121.69 | -121.69 | -137.21 | -123.84 | -109.57 | -41.64 | Upgrade
|
| Interest Expense | -10.94 | -10.94 | -5.15 | - | - | - | Upgrade
|
| Interest & Investment Income | 13.63 | 13.63 | 8.5 | 2.74 | 2.02 | 6.47 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.07 | 0.07 | - | 0.08 | -0.03 | 0.15 | Upgrade
|
| EBT Excluding Unusual Items | -118.93 | -118.93 | -133.85 | -121.02 | -107.58 | -35.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.14 | 1.14 | 2.86 | -1.17 | - | - | Upgrade
|
| Pretax Income | -117.79 | -117.79 | -131 | -122.19 | -107.58 | -35.02 | Upgrade
|
| Income Tax Expense | -1.74 | -1.74 | 2.82 | -0.43 | -28.58 | 1.15 | Upgrade
|
| Net Income | -116.05 | -116.05 | -133.82 | -121.76 | -79 | -36.17 | Upgrade
|
| Net Income to Common | -116.05 | -116.05 | -133.82 | -121.76 | -79 | -36.17 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 21 | 21 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 21 | 21 | 20 | 20 | Upgrade
|
| Shares Change (YoY) | 0.90% | 0.90% | 1.78% | 2.14% | 1.16% | -4.90% | Upgrade
|
| EPS (Basic) | -5.48 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | Upgrade
|
| EPS (Diluted) | -5.48 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | Upgrade
|
| Free Cash Flow | -96.71 | -96.71 | -112.21 | -86.91 | -70.75 | 5.64 | Upgrade
|
| Free Cash Flow Per Share | -4.57 | -4.57 | -5.35 | -4.22 | -3.51 | 0.28 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -179.92% | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | Upgrade
|
| Profit Margin | -171.58% | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | Upgrade
|
| Free Cash Flow Margin | -142.99% | -142.99% | -141.67% | -100.87% | -72.88% | 4.61% | Upgrade
|
| EBITDA | -119.36 | -119.36 | -134.84 | -120.87 | -106.24 | -38 | Upgrade
|
| EBITDA Margin | -176.47% | -176.47% | -170.24% | -140.29% | -109.44% | -31.02% | Upgrade
|
| D&A For EBITDA | 2.34 | 2.34 | 2.37 | 2.97 | 3.33 | 3.64 | Upgrade
|
| EBIT | -121.69 | -121.69 | -137.21 | -123.84 | -109.57 | -41.64 | Upgrade
|
| EBIT Margin | -179.92% | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | Upgrade
|
| Revenue as Reported | 67.64 | 67.64 | 79.2 | 86.16 | 97.07 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.